Printer Friendly

CoDa Therapeutics' Nexagon indicates increased healing in patients with chronic venous leg ulcers.

M2 PHARMA-January 11, 2013-CoDa Therapeutics' Nexagon indicates increased healing in patients with chronic venous leg ulcers(C)2013 M2 COMMUNICATIONS

United States-based CoDa Therapeutics has announced that Nexagon was well tolerated and indicated an increase in complete healing in patients with chronic venous leg ulcers in the Phase 2b study.

It was reported yesterday that the results of the study support the development of Nexagon into Phase 3 registration trials. The UNC Limb Salvage/Wound Healing Centre medical director and University of North Carolina division of vascular surgery professor and chief, Dr. William Marston, stated that the company's Phase 2b clinical results indicate a well-designed and executed dosing phase study.

Marston said, 'This data will provide clear information to choose an optimal dose and patient profile to move to a pivotal clinical trial.'

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2013 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Article Type:Clinical report
Date:Jan 11, 2013
Words:144
Previous Article:Ecolab appoints Alex Blanco as EVP.
Next Article:Elsevier acquires Aureus Sciences.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters